24 March 2025 PBAC spurns tirzepatide for subsidy, again 5 minute read Clinical Diabetes Obesity PBAC The Hill By Penny Durham Besides cost, the committee found the drug didn’t fulfill all the maker’s efficacy and safety claims. This content is for AHPRA registered professionals only.LoginJoin Now Previous Post Next Post